Therefore, as a nontoxic, efficient and adoptive immunotherapeutic strategy, the use of a vaccine of DCs co-cultured with CIKs may increase the potential of specific immune response against HCC. This evidence concerns the gene TRAF3IP2 and hepatocellular carcinoma.